Cajanol 是一种可从木豆 (Cajanus cajan (L.) Millsp.) 根中分离得到的异黄烷酮,能抑制癌细胞增殖并诱导癌细胞凋亡 (apoptosis),其机制包括促进 Bax 表达、抑制 Bcl-2 表达、激活 caspase-9 和 caspase-3、诱导 PARP 剪切、将细胞周期阻滞于 G2/M 期、产生 ROS、破坏线粒体膜电位并触发细胞色素 c 释放,同时还可诱导细菌 (bacterial) DNA 损伤、破坏细菌细胞膜并在体外发挥抗细菌活性,并可降低 PI3K 表达、抑制 Akt 和 NF-κB 的磷酸化、下调 P-gp 的表达及转运功能、恢复耐药癌细胞对 Paclitaxel 的敏感性并抑制 Paclitaxel 耐受性转移性卵巢肿瘤的生长,因此可用于乳腺癌、卵巢癌、细菌感染的相关研究。
产品编号: MS-N98400 CAS No.: 61020-70-0 分子式: C17H16O6 分子量: 316.31
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Cajanol 是一种可从木豆 (Cajanus cajan (L.) Millsp.) 根中分离得到的异黄烷酮,能抑制癌细胞增殖并诱导癌细胞凋亡 (apoptosis),其机制包括促进 Bax 表达、抑制 Bcl-2 表达、激活 caspase-9 和 caspase-3、诱导 PARP 剪切、将细胞周期阻滞于 G2/M 期、产生 ROS、破坏线粒体膜电位并触发细胞色素 c 释放,同时还可诱导细菌 (bacterial) DNA 损伤、破坏细菌细胞膜并在体外发挥抗细菌活性,并可降低 PI3K 表达、抑制 Akt 和 NF-κB 的磷酸化、下调 P-gp 的表达及转运功能、恢复耐药癌细胞对 Paclitaxel 的敏感性并抑制 Paclitaxel 耐受性转移性卵巢肿瘤的生长,因此可用于乳腺癌、卵巢癌、细菌感染的相关研究。

生物实验数据

生物活性 Cajanol is an isoflavanone isolated from the roots of Cajanus cajan (L.) Millsp. that inhibits cancer cell proliferation and induces apoptosis by promoting Bax expression, suppressing Bcl-2 expression, activating caspase-9 and caspase-3, inducing PARP cleavage, arresting the cell cycle at G2/M phase, generating ROS, disrupting mitochondrial membrane potential, and triggering cytochrome c release, while also inducing bacterial DNA damage, disrupting bacterial cell membranes, and exerting antibacterial activity in vitro, and it reduces PI3K expression, inhibits Akt and NF-κB phosphorylation, downregulates P-gp expression and transport function, restores the sensitivity of drug-resistant cancer cells to Paclitaxel, and suppresses the growth of Paclitaxel-resistant metastatic ovarian tumors, making it useful for research on breast cancer, ovarian cancer, and bacterial infections.
体外研究
(In Vitro)

Cajanol (0-316 μM; 24-72 h) 可呈时间和剂量依赖性强效抑制人乳腺癌 MCF-7 细胞的生长,72 h 后的 IC50 为 54.05 μM,48 h 后的 IC50 为 58.32 μM,24 h 后的 IC50 为 83.42 μM。
Cajanol (16-64 μM; 48 h) 可在人乳腺癌 MCF-7 细胞中诱导浓度依赖性的 G2/M 期细胞周期阻滞,诱导浓度依赖性凋亡,诱导细胞发生 DNA 片段化,诱导典型的凋亡核形态学改变,包括染色质固缩和碎裂,诱导 ROS 生成、线粒体膜电位破坏。
Cajanol (16-64 μM; 48 h) 可在人乳腺癌 MCF-7 细胞中诱导 caspase-3 和 caspase-9 激活,下调细胞中 Bcl-2 的表达并上调 Bax 的表达,诱导细胞中细胞色素 c 从线粒体向胞浆呈浓度依赖性释放,诱导 PARP 呈浓度依赖性剪切。
Cajanol (24 h) 可在体外抑制革兰氏阳性菌 (Staphylococcus epidermidis、Staphylococcus aureus、Bacillus subtilis) 和革兰氏阴性菌 (Escherichia coli、Proteus vulgaris、Pseudomonas aeruginosa) 菌株的生长,其中最敏感菌株 (Staphylococcus epidermidis、Staphylococcus aureus、Escherichia coli) 的 MIC 值为 98.90 μM,敏感性较低的菌株 (Bacillus subtilis、Proteus vulgaris、Pseudomonas aeruginosa) 的 MIC 值为 197.8 μM。
Cajanol (4-10 小时) 可在体外诱导大肠杆菌和金黄色葡萄球菌发生时间依赖性细胞死亡和膜损伤,诱导发生 DNA 切割。
Cajanol (2-16 μM; 72 h) 可浓度依赖性逆转 A2780/Taxol 和 A549/Taxol 细胞的 Paclitaxel (HY-B0015) 耐药性。
Cajanol (2-8 μM; 48 h) 可浓度依赖性地抑制 A2780/Taxol 细胞中 ABCB1 的 mRNA 表达、P-gp 蛋白。
Cajanol (2-8 μM; 48 h) 可通过降低 PI3K 表达、抑制 Akt 磷酸化及阻断 NF-κB/p65 磷酸化与核转位,以浓度依赖的方式抑制 A2780/Taxol 细胞中的 PI3K/Akt/NF-κB 信号通路。
Cajanol (2-8 μM; 2 h pre-incubation, 1 h co-incubation with rhodamine-123) 可浓度依赖性地抑制 A2780/Taxol 细胞中 P-gp 介导的外排活性,增加细胞内 rhodamine-123 的累积。

Cell Cytotoxicity Assay

Cell Line: MCF-7 human breast cancer cells
Concentration: 0, 9.88, 19.75, 39.5, 79, 158 and 316 μM
Incubation Time: 24 h; 48 h; 72 h
Result: Inhibited MCF-7 cell growth in a time- and dose-dependent manner.
Reached an IC50 value of 83.42 μM after 24 h treatment, 58.32 μM after 48 h treatment, and 54.05 μM after 72 h treatment.

Cell Cycle Analysis

Cell Line: MCF-7 human breast cancer cells
Concentration: 0, 16, 32 and 64 μM
Incubation Time: 48 h
Result: Increased the G2/M phase cell population from 19.24% (16 μM) to 47.87% (64 μM), compared to 7.55% in untreated controls.

Apoptosis Analysis

Cell Line: MCF-7 human breast cancer cells
Concentration: 0, 16, 32 and 64 μM
Incubation Time: 48 h
Result: Increased the percentage of annexinV-FITC binding MCF-7 cells in a concentration-dependent manner, reaching 12.84% (16 μM), 47.94% (32 μM), and 78.03% (64 μM).

Western Blot Analysis

Cell Line: MCF-7 human breast cancer cells
Concentration: 16-64 μM
Incubation Time: 48 h
Result: Decreased relative Bcl-2 expression from 66.89% (16 μM) to 47.20% (64 μM) in a concentration-dependent manner.
Increased relative Bax expression from 186.36% (16 μM) to 341.36% (64 μM) in a concentration-dependent manner.\nDecreased relative mitochondrial cytochrome c expression from 87.93% (16 μM) to 19.40% (64 μM) in a concentration-dependent manner.
Increased relative cytosolic cytochrome c expression from 190.04% (16 μM) to 503.91 % (64 μM) in a concentration-dependent manner.\nDecreased relative full-length PARP expression from 95.64% (16 μM) to 38.89% (64 μM) in a concentration-dependent manner.
Increased cleaved PARP expression in a concentration-dependent manner, visible as an 85 kDa protein band with disappearance of the 116 kDa band.

Cell Proliferation Assay

Cell Line: A2780/Taxol paclitaxel-resistant ovarian cancer cells, A549/Taxol paclitaxel-resistant non-small cell lung cancer cells
Concentration: 2, 4, 8, 16 μM
Incubation Time: 72 h (co-incubated with paclitaxel)
Result: Reduced the Paclitaxel IC50 in A2780/Taxol cells from 35.85 μM to 25.67 μM (2 μM), 16.25 μM (4 μM), 6.54 μM (8 μM), and 6.05 μM (16 μM), with corresponding fold resistance values of 22.52, 14.51, 5.64, and 5.50, respectively.
Reduced the paclitaxel IC50 in A549/Taxol cells from 289.34 μM to 189.43 μM (2 μM), 68.95 μM (4 μM), 27.9 μM (8 μM), and 23.76 μM (16 μM), with corresponding fold resistance values of 24.35, 9.01, 3.74, and 3.15, respectively.
Exhibited an IC50 of 28.34 μM in A2780/Taxol cells and 87.78 μM in A549/Taxol cells when used alone.

Real Time qPCR

Cell Line: A2780/Taxol paclitaxel-resistant ovarian cancer cells
Concentration: 2, 4, 8 μM
Incubation Time: 48 h
Result: Concentration-dependently downregulated ABCB1 mRNA expression, with 8 μM reducing expression to ~10% of the control level.
Did not significantly change expression of VEGF, MMP-9, Tubα1a, and Tubβ3 mRNA.

Western Blot Analysis

Cell Line: A2780/Taxol paclitaxel-resistant ovarian cancer cells
Concentration: 2, 4, 8 μM
Incubation Time: 48 h
Result: Concentration-dependently downregulated P-gp protein expression.
Did not significantly change expression of VEGF, MMP-9, α-tubulin, βIII-tubulin, MRP1, MRP2, and LRP protein.\nConcentration-dependently reduced PI3K protein expression, inhibited Akt phosphorylation, and reduced NF-κB/p65 phosphorylation and nuclear translocation.
Did not significantly change total Akt and total NF-κB/p65 protein expression.
体内研究
(In Vivo)

Cajanol (2 mM/kg;静脉注射;肿瘤植入后第 1、8 和 15 天) 可在 24 天后将 Paclitaxel 耐药性卵巢肿瘤的体积降至 680 mm3;当与 Paclitaxel 联用时,可将肿瘤体积显著降至 182.4 mm3,同时维持小鼠的体重。

Animal Model: BALB/c nude (6-week-old female, 18-20 g, subcutaneous inoculation of A2780/Taxol paclitaxel-resistant ovarian cancer cells)
Dosage: 2 mM/kg (single-agent); 2 mM/kg + 0.5 mM/kg paclitaxel (combination)
Administration: i.v.; on days 1, 8, and 15 post-tumor implantation; 24 days monitoring
Result: Achieved a final tumor volume of 680 mm3 after 24 days when administered alone.
Reduced final tumor volume to 182.4 mm3 when combined with 0.5 mM/kg paclitaxel.
Maintained an average mouse body weight of ~25 g when combined with paclitaxel.
Significantly inhibited P-gp protein expression in tumor tissues.

化学信息

分子量 316.31
分子式 C17H16O6
CAS No. 61020-70-0

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础